BACKGROUND:Chronic Lymphocytic Leukemia (CLL) is a malignant disease incurable of the lymphoid system, that affects predominantly elderly, especially in Western countries. Your treatment when necessary is based on the administration of chemotherapy, with association of fludarabine plus cyclophosphamide (FC), the most widely used schema. Recently the addition of rituximabe, a monoclonal antibody has been associated with this scheme, known as FCR. OBJECTIVES: To elaborate a budget impact analysis (BIA) of rituximab for chronic lymphocytic leukemic  for help the decision making. METHODS: A BIA of association of fludarabine plus cyclophosphamide in SUS compared to rituximab with this scheme  was performed. The analysis’ time horizon was 5 years, using a CLL prevalence of 4.4% and 25% of CLL refractory between them (1.634), considering an annual growth rate of 0.8143% and a market share of 25% and 75% according the classification of diagnosis and stage of Rai & Keating. The mean total rituximab dose considered was 375/mg/m, with an average personal weight and size of 70kg and 1,70m, which means 681,75mg per cicle. All cost purchase prices and remission rate of rituximab (22%) and stand chemiterapy (9%) were obtained at one year trial in the onco-hematology high complexity Clinical Hospital of the Faculty of Medicine of Ribeirão Preto HCFMRP / USP hospital measured in real 2012. RESULTS The budget impact of FC per year would be 38.7m reais ($17.5m) in the 1st year, considering 25% of target population, reaching approximately 135.3m reais ($60.9m) in 75% of patients. For RFC, the budget impact would be 97 million reais ($43.6m) in the 1st year, reaching 340 million reais ($153m) in 75% of patients. CONCLUSIONS: Treatment costs still impressive, considering that rituximab ’ values reach 2.5 times the clicle unit values of standart chemioperapy, fact that did not happen in other countries where they are already covered.